Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In 2021, the American Cancer Society projects 1,898,160 new cancer cases and 608,570 cancer deaths in the United States. Solid tumors account for approximately…
Eli Lilly has agreed to pay Dutch biotech Merus up to $1.66 billion in a research collaboration to develop CD3 bispecific antibody T-cell engagers. Lilly is…
Global spending on oncology medicines reached $185 billion in 2021, an 11% increase from 2020, and is forecast to reach $300 billion by 2026 driven by…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Loxo Oncology at Lilly and Merus entered an exclusive research collaboration and license agreement for up to three CD3-redirecting bispecific antibodies leveraging Merus' Biclonics platform. Merus received $40M upfront and a $20M equity investment, plus eligibility for up to $540M in development/commercialization milestones per product (~$1.6B total) and tiered royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Merus N.V. (this deal) | 2021 | $1.7B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2021 deals · Eli Lilly and Company deals · Oncology deals